What if you could streamline and accelerate your early phase development while maximizing flexibility, time and cost, so you can get the data you need faster?

The PCI Way

Speed to Study

Speed to Expertise

Speed to Patient

Speed to Approval

Speed to Launch

pci | bridge

Navigation

The PCI Way

Speed to Study

Speed to Expertise

Speed to Patient

Speed to Approval

Speed to Launch

pci | bridge

Speed to Study - Applied

Dr Rebecca Coutts

Rebecca discusses the development of an oncology product utilizing XcelodoseTM microdosing technology.



Brendan Dempsey

Brendan talks about how Speed to Study is used to help streamline early phase development in clinical trials.

Brendan Dempsey

Brendan shares a Speed to Study case study of oral solid dose capsule filling for early liver disease treatment.

Katty Roggensack

Katty shares an example of how Speed to Study helped expedite IMP study materials, to analize their impact on seasonal allergies.

FACTS

FEATURES

The PCI Way - swiftly initiating early phase trials to establish proof of concept, efficacy, and stability of your drug candidates quickly and efficiently

Agile global network with phase-specific processes to deliver scalable JIT solutions
Culture of speed, expertise and customer centricity
Flexible managerial and operational systems
Utilizing PCI Melbourne for Early Phase clinical launch

“Accelerate your drug to proof of concept with PCI’s Speed to Study solution.”

Andrew Castles
General Manager, Melbourne

"Companies that take steps to identify potential problems in advance and then proactively stop the development of an imperiled trial have a much higher likelihood of ultimately reaching the market with their drugs.”

clinicalleader.com, 'Why Do Most Clinical Trials Fail'

BENEFITS

Get up to 43.5% rebate on your costs with Australia’s R&D Tax Incentive
Reduce clinical trial waste 30-50% with JIT labeling and packaging processes
Save weeks with Rapid Ph.I & Ph.II b-GMP/TGA licensed facilities
Xcelodose® technology for cost and time-efficient early stage development and first-in-human trials
Speed up your CTN, 5 days approval post HREC review
PCIFastTrackTM- a flexible, demand led approach for time-critical studies
Access patient dosing in 6-8 weeks from IRB to HREC in Australia